Literature DB >> 11585414

Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors.

L Sui1, Y Dong, M Ohno, K Sugimoto, Y Tai, T Hando, M Tokuda.   

Abstract

OBJECTIVE: The aim of this study was to further evaluate whether the expression of p27(kip1), cyclin E, and cdk2 is related to the malignancy of ovarian tumors and whether their expressions, alone or in combination, are associated with prognosis in epithelial ovarian carcinoma.
METHODS: Immunohistochemical analysis using anti-p27(kip1), anti-cyclinE, and anti-cdk2 antibodies was carried out for 103 cases consisting of benign, borderline, and malignant ovarian tumors, and Western blot analysis and cdk2 activity assay were performed in 26 fresh ovarian tumor samples.
RESULTS: p27(kip1) expression was reduced in ovarian carcinomas in contrast to benign and borderline tumors. The expression of cyclin E and cdk2 gradually increased from benign to borderline to malignant tumors. Kaplan-Meier survival analysis showed that patients with p27(kip1) expression had a high overall survival rate. Patients with cyclin E overexpression had a low overall survival rate. When the combination of these proteins was analyzed, patients with the p27(kip1) (-)/cyclin E (++)/cdk2 (++) phenotype were significantly associated with the poorest overall survival. In multivariate Cox regression analysis, the combined phenotype of p27(kip1) (-)/cyclin E (++)/cdk2 (++) was independently related to poor prognosis.
CONCLUSIONS: Our results suggest that loss of p27(kip1) expression and overexpression of cyclin E or cdk2 were significantly associated with malignancy in ovarian tumors. p27(kip1) and cyclin E proteins may be valuable prognostic factors for epithelial ovarian carcinoma patients. Furthermore, the combined evaluation of p27(kip1)/cyclin E/cdk2 may provide the most important prognostic implication. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585414     DOI: 10.1006/gyno.2001.6308

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability.

Authors:  W Jiang; H Huang; L Ding; P Zhu; H Saiyin; G Ji; J Zuo; D Han; Y Pan; D Ding; X Ma; Y Zhang; J Wu; Q Yi; J O Liu; H Huang; Y Dang; L Yu
Journal:  Oncogene       Date:  2014-11-17       Impact factor: 9.867

Review 2.  Cell cycle control as a basis for cancer chemoprevention through dietary agents.

Authors:  Syed Musthapa Meeran; Santosh Kumar Katiyar
Journal:  Front Biosci       Date:  2008-01-01

3.  NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Authors:  Donglin Ding; Huixing Huang; Quanfu Li; Wenbo Yu; Chenji Wang; Haijie Ma; Jiaxue Wu; Yongjun Dang; Long Yu; Wei Jiang
Journal:  Cell Death Discov       Date:  2020-01-22

Review 4.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

Review 5.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

6.  Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.

Authors:  Xun Guo; Yuehan Wu; Rebecca S Hartley
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

7.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

8.  Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.

Authors:  Hannah Wingate; Agnes Puskas; Mylinh Duong; Tuyen Bui; Dana Richardson; Yanna Liu; Susan L Tucker; Carolyn Van Pelt; Laurent Meijer; Kelly Hunt; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2009-04-10       Impact factor: 4.534

9.  Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Authors:  Alicia A Goyeneche; Erin E Seidel; Carlos M Telleria
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

10.  Distinct expression pattern and post-transcriptional regulation of cell cycle genes in the glandular epithelia of avian ovarian carcinomas.

Authors:  Jin-Young Lee; Wooyoung Jeong; Ji-Hye Kim; Jinyoung Kim; Fuller W Bazer; Jae Yong Han; Gwonhwa Song
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.